Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,172,328 papers from all fields of science
Search
Sign In
Create Free Account
KW-2450
Known as:
IGF-1R/IR Inhibitor KW-2450
An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Indazoles
Piperazines
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
H. Umehara
,
Y. Maekawa
,
+9 authors
N. Ueno
Therapeutic advances in medical oncology
2018
Corpus ID: 51928216
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We…
Expand
2016
2016
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
G. Schwartz
,
M. Dickson
,
+6 authors
S. Akinaga
Cancer science
2016
Corpus ID: 5968358
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize…
Expand
2015
2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
K. Kai
,
Kimie Kondo
,
+11 authors
N. Ueno
Molecular Cancer Therapeutics
2015
Corpus ID: 831913
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not…
Expand
2015
2015
Antitumor Activity of KW-2450 against Triple- NegativeBreastCancerbyInhibitingAuroraAand
K. Kai
,
Kimie Kondo
,
+11 authors
N. Ueno
2015
Corpus ID: 89667148
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not…
Expand
2013
2013
Abstract 920: KW-2450, a novel IGF-1R/IR inhibitor, enhances the antitumor effect of lapatinib, letrozole or 4-hydroxy-tamoxifen in breast cancer cells.
H. Umehara
,
F. Koizumi
,
+10 authors
S. Soga
2013
Corpus ID: 72908027
[Background] Both the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptors (IR) have been found to be promising…
Expand
2013
2013
Abstract 2431: IGF1R/IR axis is a novel treatment target in ER-negative breast cancer.
K. Kai
,
Kimie Kondo
,
N. Ueno
2013
Corpus ID: 72181266
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background/Hypothesis: Insulin growth factor-1…
Expand
2013
2013
Abstract P2-09-04: Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC)
K. Kai
,
Kimie Kondo
,
C. Bartholomeusz
,
V. Valero
,
G. Hortobagyi
,
N. Ueno
2013
Corpus ID: 85250095
Recent studies found that TNBC had a highly activated profile in the insulin-like growth factor 1 receptor (IGF-1R)/insulin…
Expand
2011
2011
Abstract 3605: KW-2450, a novel orally-active dual IGF1R/IR inhibitor: Antitumor effects in vitro and in vivo
Y. Maekawa
,
F. Koizumi
,
+11 authors
S. Soga
2011
Corpus ID: 72778784
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL KW-2450 is an orally active, multi-kinase inhibitor…
Expand
2011
2011
Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors.
M. Dickson
,
P. LoRusso
,
+5 authors
G. Schwartz
Journal of clinical oncology : official journal…
2011
Corpus ID: 27316054
3078 Background: KW-2450, a potent small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE